Table 1. Rates of sustained... | American Society of Hematology

Table 1.

Rates of sustained MRD-negativity status in transplant-ineligible NDMM

MRD negativity (10^‒5)	MAIA			ALCYONE*
MRD negativity (10^‒5)	D-Rd	Rd	P†	D-VMP	VMP	P†
Intention-to-treat	n = 368	n = 369		n = 350	n = 356
MRD-negative status, n (%)	106 (28.8)	34 (9.2)	<.0001	94 (26.9)	25 (7.0)	<.0001
≥6 mo sustained	55 (14.9)	16 (4.3)	<.0001	55 (15.7)	16 (4.5)	<.0001
≥12 mo sustained	40 (10.9)	9 (2.4)	<.0001	49 (14.0)	10 (2.8)	<.0001
Complete response or better	n = 182	n = 100		n = 160	n = 90
MRD-negative status, n (%)	106 (58.2)	34 (34.0)	.0001	94 (58.8)	25 (27.8)	<.0001
≥6 mo sustained	55 (30.2)	16 (16.0)	.0097	55 (34.4)	16 (17.8)	.0055
≥12 mo sustained	40 (22.0)	9 (9.0)	.0053	49 (30.6)	10 (11.1)	.0006

MRD negativity (10^‒5)	MAIA			ALCYONE*
MRD negativity (10^‒5)	D-Rd	Rd	P†	D-VMP	VMP	P†
Intention-to-treat	n = 368	n = 369		n = 350	n = 356
MRD-negative status, n (%)	106 (28.8)	34 (9.2)	<.0001	94 (26.9)	25 (7.0)	<.0001
≥6 mo sustained	55 (14.9)	16 (4.3)	<.0001	55 (15.7)	16 (4.5)	<.0001
≥12 mo sustained	40 (10.9)	9 (2.4)	<.0001	49 (14.0)	10 (2.8)	<.0001
Complete response or better	n = 182	n = 100		n = 160	n = 90
MRD-negative status, n (%)	106 (58.2)	34 (34.0)	.0001	94 (58.8)	25 (27.8)	<.0001
≥6 mo sustained	55 (30.2)	16 (16.0)	.0097	55 (34.4)	16 (17.8)	.0055
≥12 mo sustained	40 (22.0)	9 (9.0)	.0053	49 (30.6)	10 (11.1)	.0006

MRD data on durability from the ITT population of ALCYONE were reported previously.¹¹

P value was calculated using Fisher's exact test.